GSK in talks with Trump administration on U.S. drug pricing, CEO says

LONDON, July 30 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressure from Washington to rein in prices.

GSK CEO Emma Walmsley said on a call with journalists after the company posted second-quarter profits above analyst expectations that the discussions with the U.S. administration are "about how to make sure discounts are passed on to patients and pricing is sustainable, both for the government and also for industry."